Cargando…
CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment
CCL22 is a macrophage-derived immunosuppressive chemokine that recruits regulatory T cells through the CCL22:CCR4 axis. CCL22 was shown to play a key role in suppressing anti-cancer immune responses in different cancer types. Recently, we showed that CCL22-specific T cells generated from cancer pati...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427044/ https://www.ncbi.nlm.nih.gov/pubmed/36052217 http://dx.doi.org/10.1080/2162402X.2022.2115655 |
_version_ | 1784778814045290496 |
---|---|
author | Lecoq, Inés Kopp, Katharina L. Chapellier, Marion Mantas, Panagiotis Martinenaite, Evelina Perez-Penco, Maria Rønn Olsen, Lars Zocca, Mai-Britt Wakatsuki Pedersen, Ayako Andersen, Mads Hald |
author_facet | Lecoq, Inés Kopp, Katharina L. Chapellier, Marion Mantas, Panagiotis Martinenaite, Evelina Perez-Penco, Maria Rønn Olsen, Lars Zocca, Mai-Britt Wakatsuki Pedersen, Ayako Andersen, Mads Hald |
author_sort | Lecoq, Inés |
collection | PubMed |
description | CCL22 is a macrophage-derived immunosuppressive chemokine that recruits regulatory T cells through the CCL22:CCR4 axis. CCL22 was shown to play a key role in suppressing anti-cancer immune responses in different cancer types. Recently, we showed that CCL22-specific T cells generated from cancer patients could kill CCL22-expressing tumor cells and directly influence the levels of CCL22 in vitro. The present study aimed to provide a rationale for developing a CCL22-targeting immunotherapy. Vaccination with CCL22-derived peptides induced CCL22-specific T-cell responses in both BALB/c and C57BL/6 mice, assessed by interferon-γ secretion ex vivo. Anti-tumor efficacy of the peptides was evaluated in mouse models engrafted with syngeneic tumor models showing a reduced tumor growth and prolonged survival of the treated mice. Vaccination induced changes in the cellular composition of immune cells that infiltrated the tumor microenvironment assessed with multicolor flow cytometry. In particular, the infiltration of CD8(+) cells and M1 macrophages increased, which increased the CD8/Treg and the M1/M2 macrophage ratio. This study provided preclinical evidence that targeting CCL22 with CCL22 peptide vaccines modulated the immune milieu in the tumor microenvironment. This modulation led to an augmentation of anti-tumor responses. This study provided a rationale for developing a novel immunotherapeutic modality in cancer. |
format | Online Article Text |
id | pubmed-9427044 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-94270442022-08-31 CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment Lecoq, Inés Kopp, Katharina L. Chapellier, Marion Mantas, Panagiotis Martinenaite, Evelina Perez-Penco, Maria Rønn Olsen, Lars Zocca, Mai-Britt Wakatsuki Pedersen, Ayako Andersen, Mads Hald Oncoimmunology Original Research CCL22 is a macrophage-derived immunosuppressive chemokine that recruits regulatory T cells through the CCL22:CCR4 axis. CCL22 was shown to play a key role in suppressing anti-cancer immune responses in different cancer types. Recently, we showed that CCL22-specific T cells generated from cancer patients could kill CCL22-expressing tumor cells and directly influence the levels of CCL22 in vitro. The present study aimed to provide a rationale for developing a CCL22-targeting immunotherapy. Vaccination with CCL22-derived peptides induced CCL22-specific T-cell responses in both BALB/c and C57BL/6 mice, assessed by interferon-γ secretion ex vivo. Anti-tumor efficacy of the peptides was evaluated in mouse models engrafted with syngeneic tumor models showing a reduced tumor growth and prolonged survival of the treated mice. Vaccination induced changes in the cellular composition of immune cells that infiltrated the tumor microenvironment assessed with multicolor flow cytometry. In particular, the infiltration of CD8(+) cells and M1 macrophages increased, which increased the CD8/Treg and the M1/M2 macrophage ratio. This study provided preclinical evidence that targeting CCL22 with CCL22 peptide vaccines modulated the immune milieu in the tumor microenvironment. This modulation led to an augmentation of anti-tumor responses. This study provided a rationale for developing a novel immunotherapeutic modality in cancer. Taylor & Francis 2022-08-29 /pmc/articles/PMC9427044/ /pubmed/36052217 http://dx.doi.org/10.1080/2162402X.2022.2115655 Text en © 2022 IO Biotech ApS. Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Lecoq, Inés Kopp, Katharina L. Chapellier, Marion Mantas, Panagiotis Martinenaite, Evelina Perez-Penco, Maria Rønn Olsen, Lars Zocca, Mai-Britt Wakatsuki Pedersen, Ayako Andersen, Mads Hald CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment |
title | CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment |
title_full | CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment |
title_fullStr | CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment |
title_full_unstemmed | CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment |
title_short | CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment |
title_sort | ccl22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427044/ https://www.ncbi.nlm.nih.gov/pubmed/36052217 http://dx.doi.org/10.1080/2162402X.2022.2115655 |
work_keys_str_mv | AT lecoqines ccl22basedpeptidevaccinesinduceanticancerimmunitybymodulatingtumormicroenvironment AT koppkatharinal ccl22basedpeptidevaccinesinduceanticancerimmunitybymodulatingtumormicroenvironment AT chapelliermarion ccl22basedpeptidevaccinesinduceanticancerimmunitybymodulatingtumormicroenvironment AT mantaspanagiotis ccl22basedpeptidevaccinesinduceanticancerimmunitybymodulatingtumormicroenvironment AT martinenaiteevelina ccl22basedpeptidevaccinesinduceanticancerimmunitybymodulatingtumormicroenvironment AT perezpencomaria ccl22basedpeptidevaccinesinduceanticancerimmunitybymodulatingtumormicroenvironment AT rønnolsenlars ccl22basedpeptidevaccinesinduceanticancerimmunitybymodulatingtumormicroenvironment AT zoccamaibritt ccl22basedpeptidevaccinesinduceanticancerimmunitybymodulatingtumormicroenvironment AT wakatsukipedersenayako ccl22basedpeptidevaccinesinduceanticancerimmunitybymodulatingtumormicroenvironment AT andersenmadshald ccl22basedpeptidevaccinesinduceanticancerimmunitybymodulatingtumormicroenvironment |